NO3040075T3 - - Google Patents

Info

Publication number
NO3040075T3
NO3040075T3 NO14200543A NO14200543A NO3040075T3 NO 3040075 T3 NO3040075 T3 NO 3040075T3 NO 14200543 A NO14200543 A NO 14200543A NO 14200543 A NO14200543 A NO 14200543A NO 3040075 T3 NO3040075 T3 NO 3040075T3
Authority
NO
Norway
Application number
NO14200543A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3040075T3 publication Critical patent/NO3040075T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO14200543A 2014-12-30 2014-12-30 NO3040075T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14200543.8A EP3040075B1 (en) 2014-12-30 2014-12-30 C-19 steroids for inhibiting neovascularization

Publications (1)

Publication Number Publication Date
NO3040075T3 true NO3040075T3 (cg-RX-API-DMAC10.html) 2018-02-10

Family

ID=52146363

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14200543A NO3040075T3 (cg-RX-API-DMAC10.html) 2014-12-30 2014-12-30

Country Status (17)

Country Link
US (1) US10426785B2 (cg-RX-API-DMAC10.html)
EP (2) EP3040075B1 (cg-RX-API-DMAC10.html)
JP (1) JP6788592B2 (cg-RX-API-DMAC10.html)
KR (1) KR102481553B1 (cg-RX-API-DMAC10.html)
CN (2) CN107206010B (cg-RX-API-DMAC10.html)
CA (1) CA2972324C (cg-RX-API-DMAC10.html)
DK (1) DK3040075T3 (cg-RX-API-DMAC10.html)
EA (2) EA039485B1 (cg-RX-API-DMAC10.html)
ES (1) ES2651442T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20171875T1 (cg-RX-API-DMAC10.html)
HU (1) HUE037698T2 (cg-RX-API-DMAC10.html)
NO (1) NO3040075T3 (cg-RX-API-DMAC10.html)
PL (1) PL3040075T3 (cg-RX-API-DMAC10.html)
PT (1) PT3040075T (cg-RX-API-DMAC10.html)
RS (1) RS56621B1 (cg-RX-API-DMAC10.html)
SI (1) SI3040075T1 (cg-RX-API-DMAC10.html)
WO (1) WO2016107778A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632445A1 (en) 2018-10-04 2020-04-08 Curadis GmbH Combinations with a c-19 steroid for treating cancers
CN114149923B (zh) * 2021-11-19 2024-03-08 大连理工大学 内皮细胞-平滑肌细胞共培养的单流道微芯片模型的构建方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
RS20150135A1 (sr) * 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
AU2005222934B2 (en) * 2004-03-12 2010-06-17 Entremed, Inc. Antiangiogenic agents
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
EP1854465A1 (en) * 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
DK2060300T3 (da) * 2007-11-13 2015-06-22 Curadis Gmbh C-19-steroider til terapeutiske anvendelser
CN101619089B (zh) * 2009-07-28 2011-07-20 陈大刚 抗肿瘤药物cl168、其合成方法及应用

Also Published As

Publication number Publication date
RS56621B1 (sr) 2018-03-30
EP3215161A1 (en) 2017-09-13
WO2016107778A1 (en) 2016-07-07
HRP20171875T1 (hr) 2018-01-26
CN107206010A (zh) 2017-09-26
ES2651442T3 (es) 2018-01-26
EA202190993A3 (ru) 2021-10-29
EP3040075B1 (en) 2017-09-13
US10426785B2 (en) 2019-10-01
CN113117089A (zh) 2021-07-16
JP2018508474A (ja) 2018-03-29
CN107206010B (zh) 2021-12-21
CA2972324C (en) 2023-09-26
US20170360804A1 (en) 2017-12-21
EA201791209A1 (ru) 2017-11-30
PT3040075T (pt) 2017-12-20
EA039485B1 (ru) 2022-02-01
EP3040075A1 (en) 2016-07-06
JP6788592B2 (ja) 2020-11-25
DK3040075T3 (en) 2017-12-18
KR102481553B1 (ko) 2022-12-26
KR20170100539A (ko) 2017-09-04
SI3040075T1 (en) 2018-04-30
PL3040075T3 (pl) 2018-03-30
CA2972324A1 (en) 2016-07-07
EA202190993A2 (ru) 2021-08-31
HUE037698T2 (hu) 2018-09-28

Similar Documents

Publication Publication Date Title
BR112016017664A2 (cg-RX-API-DMAC10.html)
BR112016017979A2 (cg-RX-API-DMAC10.html)
BR112016015519A2 (cg-RX-API-DMAC10.html)
BR112016015890A2 (cg-RX-API-DMAC10.html)
BR112016003131A2 (cg-RX-API-DMAC10.html)
BR112016016490A2 (cg-RX-API-DMAC10.html)
BR112016016546A2 (cg-RX-API-DMAC10.html)
BR112016018264A2 (cg-RX-API-DMAC10.html)
BR112016017103A2 (cg-RX-API-DMAC10.html)
BR112016016612A2 (cg-RX-API-DMAC10.html)
BR112016017031A2 (cg-RX-API-DMAC10.html)
BR112016016924A2 (cg-RX-API-DMAC10.html)
BR112016016421A2 (cg-RX-API-DMAC10.html)
BR112016016106A2 (cg-RX-API-DMAC10.html)
BR112016012568A2 (cg-RX-API-DMAC10.html)
BR112016016558A2 (cg-RX-API-DMAC10.html)
BR112016015798A2 (cg-RX-API-DMAC10.html)
BR112016017960A2 (cg-RX-API-DMAC10.html)
BR112016015915A2 (cg-RX-API-DMAC10.html)
BR112016018252A2 (cg-RX-API-DMAC10.html)
BR112016017356A2 (cg-RX-API-DMAC10.html)
BR112016016459A2 (cg-RX-API-DMAC10.html)
BR112016003522A2 (cg-RX-API-DMAC10.html)
BR112016014482A2 (cg-RX-API-DMAC10.html)
BR112016018021A2 (cg-RX-API-DMAC10.html)